New clause 50 debated and negatived on division (4 to 9). New clause 51 debated and withdrawn. New clause 52 negatived on division (1 to 9). New clause 56 negatived on division (1 to 9). New clause 57, discussed with new clauses 58 and 104, debated and withdrawn. New clause 66 debated and negatived on division (4 to 8). New clause 72 debated and negatived on division (2 to 9). New clause 76 negatived on division (1 to 13). New clause 77 debated and withdrawn. New clause 81, discussed with new clause 82, debated and negatived on division (4 to 9). New clause 82 negatived on division (4 to 9). New clause 83 debated and negatived on division (4 to 10). New clause 84 negatived on division (5 to 9). New clause 85, discussed with new clause 98, debated and negatived on division (5 to 9). New clause 86 debated and negatived on division (4 to 9). New clause 87, discussed with new clause 113, debated and negatived on division (5 to 9). New clause 96, discussed with new clause 97, debated and withdrawn. New clause 97 negatived on division (5 to 9). New clause 98 negatived on division (5 to 9). New clause 99 debated and negatived on division (4 to 9). New clause 101 debated and negatived on division (4 to 9). New clause 104 negatived on division (5 to 9). New clause 105, discussed with new clause 106, debated and negatived on division (4 to 9). New clause 106 negatived on division (4 to 9). New clause 108, discussed with new clause 109, debated and withdrawn. New clause 109 negatived on division (5 to 9). New clause 112, discussed with new clauses 110 and 111, debated and negatived on division (4 to 9). New schedule 1 agreed to. Clauses 68 and 69 agreed to. Clause 70, as amended, agreed to. Amendment 37 to clause 71 negatived on division (4 to 9). Amendment 38 to clause 71 negatived on division (4 to 9). Amendment 39 to clause 71 negatived on division (5 to 9). Clause 71, as amended, agreed to. Clause 72 agreed to. Bill, as amended, to be reported (Bill 131). Written evidence reported to the House.

New clause 50 debated and negatived on division (4 to 9). New clause 51 debated and withdrawn. New clause 52 negatived on division (1 to 9). New clause 56 negatived on division (1 to 9). New clause 57, discussed with new clauses 58 and 104, debated and withdrawn. New clause...

Clause 1 debated with Clauses 2 and 3, further clauses and new clauses. Clauses 1 to 6 agreed to. Clause 5, amendment 59 negatived on division (3 to 9). Clause 6, amendment 58 negatived on division (5 to 9). Clause 7 under consideration.

Clause 1 debated with Clauses 2 and 3, further clauses and new clauses. Clauses 1 to 6 agreed to. Clause 5, amendment 59 negatived on division (3 to 9). Clause 6, amendment 58 negatived on division (5 to 9). Clause 7 under consideration.

Lords statement on the effect of VAT on the availability of medicines through compassionate use schemes.

Lords statement on the effect of VAT on the availability of medicines through compassionate use schemes.

My Lords, I thank the Minister for accepting this Urgent Question repeat. Life science companies have warned that the decision to charge VAT on early access and the innovative medicines that they provide free of charge could lead to them ending providing these free treatments to patients before routine NHS...

My Lords, I thank the Minister for accepting this Urgent Question repeat. Life science companies have warned that the decision to charge VAT on early access and the innovative medicines that they provide free of charge could lead to them ending providing these free treatments to patients before routine NHS...

It is important to say, first, that this is not a new policy. There is recognition that while early access and compassionate use programmes are crucial, they are voluntary for pharma companies, which are aware, as I say, that VAT

is applicable in these instances; it has been in place...

It is important to say, first, that this is not a new policy. There is recognition that while early access and compassionate use programmes are crucial, they are voluntary for pharma companies, which are aware, as I say, that VAT

is applicable in these instances; it has been in place...

My Lords, compassionate use and early access schemes are often the only way for patients with rare cancers to access life-extending medicines. What assurance can the Minister give that HMRC’s approach to VAT will not result in patients losing access to these vital treatments? What discussions about the impact has...

My Lords, compassionate use and early access schemes are often the only way for patients with rare cancers to access life-extending medicines. What assurance can the Minister give that HMRC’s approach to VAT will not result in patients losing access to these vital treatments? What discussions about the impact has...

Cancer charities are important in this area, and we are certainly engaging with them; they are very invested partners. I understand why people are concerned. This is not instead of the NHS. NHS medicines are provided on the advice and guidance of NICE, and that absolutely continues. As I say,...

Cancer charities are important in this area, and we are certainly engaging with them; they are very invested partners. I understand why people are concerned. This is not instead of the NHS. NHS medicines are provided on the advice and guidance of NICE, and that absolutely continues. As I say,...

My Lords, do the Government recognise that it has been estimated that, for each pound invested in research, there is an approximate 25p return on that in perpetuity. Therefore, we should avoid anything which disincentivises research investment in this country, which would include the inability to recruit patients if they...

My Lords, do the Government recognise that it has been estimated that, for each pound invested in research, there is an approximate 25p return on that in perpetuity. Therefore, we should avoid anything which disincentivises research investment in this country, which would include the inability to recruit patients if they...

Indeed, we will. I can tell the noble Baroness how important speeding up access to medicines is. That is why, in April, we introduced the joint MHRA-NICE pathway for medicines, which will speed up access to new medicines by some three to six very valuable months. We have also brought...

Indeed, we will. I can tell the noble Baroness how important speeding up access to medicines is. That is why, in April, we introduced the joint MHRA-NICE pathway for medicines, which will speed up access to new medicines by some three to six very valuable months. We have also brought...

My Lords, going back to the question about access to compassionate medicine, as I understand, the Minister just stated that medicines that are not yet authorised or licensed can be issued if companies agree to provide them for free, and that HMRC charges VAT on them. If the medicines are...

My Lords, going back to the question about access to compassionate medicine, as I understand, the Minister just stated that medicines that are not yet authorised or licensed can be issued if companies agree to provide them for free, and that HMRC charges VAT on them. If the medicines are...

I am sure that the noble Lord would not want me to be quoted as suggesting that VAT should be charged on chocolates given free in shops, so I will not. The way in which VAT is calculated is a long-standing arrangement that companies are aware of. The medicines are...

I am sure that the noble Lord would not want me to be quoted as suggesting that VAT should be charged on chocolates given free in shops, so I will not. The way in which VAT is calculated is a long-standing arrangement that companies are aware of. The medicines are...

Can I bring the noble Baroness back to the last part of my noble friend’s question? It looks as though the VAT department in HMRC is behaving most peculiarly. First, it lost the case about VAT on entry to the Great Yorkshire Show, yet it is fighting every single show...

Can I bring the noble Baroness back to the last part of my noble friend’s question? It looks as though the VAT department in HMRC is behaving most peculiarly. First, it lost the case about VAT on entry to the Great Yorkshire Show, yet it is fighting every single show...

Again, I appreciate the invitation to enter into conversations about VAT more widely, which I will resist. Certainly, HMRC is aware of its role. We are trying to find the right way forward with HMRC while the issues are resolved, because patients are at the heart of this. HMRC is...

Again, I appreciate the invitation to enter into conversations about VAT more widely, which I will resist. Certainly, HMRC is aware of its role. We are trying to find the right way forward with HMRC while the issues are resolved, because patients are at the heart of this. HMRC is...

What data is there on patients who have been or will be denied treatments that they would otherwise have had? Does the Minister have any estimate of the amount of revenue expected to be raised from this? Are there plans for proper exemptions for patients who are in desperate need...

What data is there on patients who have been or will be denied treatments that they would otherwise have had? Does the Minister have any estimate of the amount of revenue expected to be raised from this? Are there plans for proper exemptions for patients who are in desperate need...

I do not have the specific figures, but if I can access them, I would be happy to have noble Baroness receive them. It is important to step back here. As mentioned by the noble Baroness, Lady Pidgeon, patients are at the core of this and, as I said to...

I do not have the specific figures, but if I can access them, I would be happy to have noble Baroness receive them. It is important to step back here. As mentioned by the noble Baroness, Lady Pidgeon, patients are at the core of this and, as I said to...

This briefing provides an overview of the government’s 10 Year Health Plan for England, published in July 2025. It also includes a summary of some of the key stakeholder responses and analysis, and updates on implementation.

This briefing provides an overview of the government’s 10 Year Health Plan for England, published in July 2025. It also includes a summary of some of the key stakeholder responses and analysis, and updates on implementation.

To ask the Secretary of State for Health and Social Care, when his Department plans to consult on reforms to the UK’s Substances of Human Origin; and whether that consultation will include proposals on (a) innovation, (b) patient safety and (c) donor protection.

To ask the Secretary of State for Health and Social Care, when his Department plans to consult on reforms to the UK’s Substances of Human Origin; and whether that consultation will include proposals on (a) innovation, (b) patient safety and (c) donor protection.

Fit for the future: The 10 year health plan for England. CP 1350. 168p.

Fit for the future: The 10 year health plan for England. CP 1350. 168p.